1Trivedi M,Rush AJ,Wisniewski SR,et al.Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D:implications for clinical practice.Am J Psych.2006;163:28-40.
3Zarate CA,Singh JB,Carlson PJ,et al.A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.Arch Gen Psychiatry,2006;63(8):856-864.
4aan het Rot M,Collins KA,Murrough JW,et al.Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.Biol Psychiatry,2010;67(2):139-145.
5Glue P,Gulati A,Le Nedelec M,et al.Dose-and exposure response to ketamine in depression.Biol Psychiatry,2011;70(4):e9-10.
6Price RB,Nock MK,Charney DS,et al.Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression.Biol Psychiatry,2009;66:522-526.
7Larkin GL,Beautrais AL.A preliminarynaturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.Int J Neuropsychopharmacol,2011;14:1127-1131.
8Lee N,Liu BY,Banasr RJ,et al.m TOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.Science,2010;329:959-964.
9Maeng S,Zarate CA,Du J,et al.Cellular mechanisms underlying the antidepressant effects of ketamine:role of-amino-3 -hydroxy-5-methylisoxazole-4-propionic acid receptors Biol Psychiatry,2008;63:349-352.
10Skolnick P.AMPA Receptors:A Target for Novel Antidepressants?Biol Psychiatry,2008;63:347-348.
